BioGaia AB (publ) (BIOGY) Stock Price, News & Analysis

Company Overview

BioGaia AB (publ) is a Sweden-based biotechnology company specializing in the development, manufacturing and marketing of probiotic products for human and animal health. The company’s core research centers on select Lactobacillus reuteri strains, supported by extensive clinical studies to promote digestive wellness, immune support and oral health. BioGaia collaborates with academic institutions and healthcare organizations to translate scientific findings into consumer and medical applications.

BioGaia’s product portfolio includes probiotic drops, chewable tablets and oral health lozenges designed for infants, children and adults. The company also supplies clinically oriented nutritional supplements and medical foods under its own brand and through partnerships with pharmaceutical and consumer health companies. In the animal health segment, BioGaia offers tailored probiotic solutions to support gastrointestinal balance in livestock and companion animals.

Products are distributed in more than 90 countries via a network of distributors, pharmacies, hospitals and retail chains. BioGaia maintains regional offices and subsidiaries across Europe, North America and Asia, and has formed strategic alliances with global food, beverage and healthcare groups to incorporate its probiotic strains into infant formulas, dairy products and other consumer items.

Founded in 1990 and headquartered in Stockholm, BioGaia AB (publ) has been listed on Nasdaq Stockholm’s small cap segment since 2004 and trades in the United States on the OTC Markets under the symbol BIOGY. The company’s executive team brings together expertise in microbiology, clinical research and international business to drive ongoing innovation and expand BioGaia’s presence in both consumer and clinical markets worldwide.

Key Stats

• Today's Range: $11.25 to $11.25
• 50-Day Range: $8.79 to $11.46
• 52-Week Range: $8.79 to $11.46
• Volume: N/A
• Average Volume: 4,516 shs
• Market Capitalization: N/A
• P/E Ratio: 2.68
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

BIOGY Stock Analysis - Frequently Asked Questions

How have BIOGY shares performed this year?

BioGaia AB (publ)'s stock was trading at $10.00 at the beginning of 2025. Since then, BIOGY stock has increased by 12.5% and is now trading at $11.25.

When did BioGaia AB (publ)'s stock split?

BioGaia AB (publ)'s stock split on the morning of Thursday, May 26th 2022.The 2.5-1 split was announced on Thursday, May 26th 2022. The newly issued shares were issued to shareholders after the closing bell on Thursday, May 26th 2022. An investor that had 100 shares of stock prior to the split would have 250 shares after the split.

How do I buy shares of BioGaia AB (publ)?

Shares of BIOGY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 10/07/2025
• Next Earnings (Estimated): 10/20/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:BIOGY
• CIK: 1572957
• Web: www.biogaia.com
• Phone: (685) 552-9300
• Fax: N/A
• Employees: 200
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: 2.68
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A